Traws Pharma, Inc. (TRAW) - Dilution Analysis

10-Q filing | 15.2M shares outstanding

S-3 filing: This S-3 filing relates to the possible resale or other disposition from time to time by the selling stockholders of up to an aggregate of 35,897,514 shares of the Company's common stock.

8-K filing: Traws Pharma, Inc. priced a private placement offering of 5,982,919 shares of common stock (or pre-funded warrants in lieu), Series A warrants to purchase up to 5,982,919 shares, Series B warrants to purchase up to 5,982,919 shares, and Series C warrants to purchase up to 17,948,757 shares, for gross proceeds of approximately $10,000,000 before fees and expenses. ($10.0M proceeds)

10-Q filing | 8.0M shares outstanding

10-Q filing | 7.1M shares outstanding

10-Q filing | 5.6M shares outstanding

10-K filing | 0.8M shares outstanding

8-K filing: Traws Pharma, Inc. amended Series A Warrants to change change of control threshold, revise volatility rate, and remove adjustments to the exercise price in the event of a reverse stock split, stock consolidation, or a recapitalization.

8-K filing: Traws Pharma, Inc. closed an offering of Class A and Class B Units on December 31, 2024, with gross proceeds of approximately $20 million before deducting fees and expenses. ($40.0M proceeds)

S-3 filing: This S-3 filing registers 7,230,301 shares of common stock for resale by selling stockholders, consisting of shares issuable upon exercise of pre-funded and Series A warrants, with the company not receiving proceeds from the sale but potentially receiving exercise prices upon warrant exercise.

8-K filing: Traws Pharma, Inc. completed an offering of Class A and Class B Units, consisting of shares of common stock, pre-funded warrants, and Series A warrants, with gross proceeds of approximately $20 million at closing and potential additional proceeds of $52.6 million upon exercise of the Series A warrants. ($20.0M proceeds)

10-Q filing | 3.0M shares outstanding

10-Q filing | 25.3M shares outstanding

S-3 filing: This S-3 filing relates to the possible resale or other disposition of up to 128,942,761 shares of Common Stock by selling stockholders.

10-Q filing | 21.0M shares outstanding

8-K filing: Onconova Therapeutics acquired Trawsfynydd Therapeutics, issuing 3,549,538 shares of common stock and 10,359.0916 shares of Series C Preferred Stock to Trawsfynydd stockholders, and also issued 496,935 shares of common stock and 1,578.2120 shares of Series C Preferred Stock to investors in a private placement. ($28.0M proceeds)

10-K filing | 21.0M shares outstanding

10-Q filing | 21.0M shares outstanding

10-Q filing | 21.0M shares outstanding

S-3 filing: Registration of common stock, preferred stock, debt securities, warrants and units for an aggregate offering price not to exceed $150,000,000.

10-Q filing | 21.0M shares outstanding

10-K filing | 20.9M shares outstanding

10-Q filing | 20.9M shares outstanding

10-Q filing | 20.9M shares outstanding

10-Q filing | 20.9M shares outstanding

10-K filing | 12.4M shares outstanding

10-Q filing | 12.4M shares outstanding

10-Q filing | 12.4M shares outstanding

8-K filing: Stock split 1-for-15 | Outstanding: 236,714,031 → 15

10-Q filing | 236.7M shares outstanding

10-K filing | 236.6M shares outstanding

10-Q filing | 184.9M shares outstanding

10-Q filing | 179.7M shares outstanding

10-Q filing | 168.7M shares outstanding

S-3/A filing: Onconova Therapeutics, Inc. files an S-3/A amendment to register and offer Common Stock, Preferred Stock, Debt Securities, Warrants and Units up to $150,000,000, and 113 Shares of Common Stock Offered by Selling Stockholders.

S-3 filing: Onconova Therapeutics files an S-3 registration statement to offer and sell up to $150,000,000 of common stock, preferred stock, debt securities, warrants and units, and 113 shares of common stock offered by selling stockholders.

10-K filing | 167.3M shares outstanding

8-K filing: Onconova Therapeutics, Inc. closed a registered direct offering of 27,662,518 shares of common stock at a purchase price of $0.3615 per share, for aggregate gross proceeds of approximately $10.0 million on January 3, 2020. ($10.0M proceeds)